Gemcitabine News and Research

RSS

Gemcitabine is the active ingredient in a drug that is used to treat pancreatic cancer that is advanced or has spread. It is also used together with other drugs to treat breast cancer that has spread, advanced ovarian cancer, and non-small cell lung cancer that is advanced or has spread. It is also being studied in the treatment of other types of cancer. Gemcitabine blocks the cell from making DNA and may kill cancer cells. It is a type of antimetabolite

SWOG scientists to deliver online presentations at ASCO20 Virtual Scientific Program

Researchers from SWOG, a cancer clinical trials group funded by the National Cancer Institute (NCI), part of the National Institutes of Health, will make 31 presentations as part of the ASCO20 Virtual Scientific Program, the online annual meeting of the American Society of Clinical Oncology (ASCO), which runs May 29-31.

19 May 2020

Talazoparib did not show overall survival benefit in patients with advanced BRCA-mutated breast cancer

New data from the Phase III EMBRACA trial led by researchers at The University of Texas MD Anderson Cancer Center found the PARP inhibitor talazoparib did not demonstrate a statistically significant overall survival (OS) benefit for patients with metastatic HER2-negative breast cancer and mutations in the BRCA1/2 genes.

27 Apr 2020

Despite failures, chemotherapy still promising against fatal pediatric brain cancer

The pediatric brain cancer known as diffuse intrinsic pontine glioma is almost uniformly fatal. In part, this is due to where and how it grows, forming as a diffuse net of cells in a part of the brainstem called the pons, which controls essential functions like breathing and swallowing.

25 Mar 2020

Overview of prognostic and predictive factors in pancreatic cancer

Oncotarget Volume 11, Issue 10 reported that there are not standardized predictive biomarkers able to identify patients who benefit most from treatments.

13 Mar 2020

The Pancreatic Cancer Collective awards additional funding of $16 million for new therapies

The Pancreatic Cancer Collective, the strategic partnership of Lustgarten Foundation and Stand Up To Cancer, has awarded additional funding of up to $16 million to four teams of top researchers as part of its "New Therapies Challenge Grants," the American Association for Cancer Research, Scientific Partner of SU2C, announced today.

5 Mar 2020

Inexpensive drug may be used to counteract treatment resistance in patients with leukemia

A common and inexpensive drug may be used to counteract treatment resistance in patients with acute myeloid leukemia, one of the most common forms of blood cancer.

17 Jan 2020

Atlantic Health System Cancer Care enrolling patients in five pancreatic cancer studies

November is National Pancreatic Cancer Awareness month. This year alone, more than 56,000 Americans will be diagnosed with pancreatic cancer. Pancreatic tumors are particularly aggressive and hard to treat "due to a mutational profile that makes it resistant to therapies that work better for other tumor types," explains Angela Alistar, MD, medical director of GI Oncology at Morristown Medical Center.

30 Oct 2019

Certain fungi increase pancreatic cancer risk, study finds

Certain fungi move from the gut to the pancreas, expand their population more than a thousand-fold, and encourage pancreatic cancer growth, a new study finds.

2 Oct 2019

Scientists identify pathway for treatment-resistant lung cancer

A big way chemotherapy works is by prompting cancer cells to commit suicide, and scientists have found a pathway the most common lung cancer walks to avoid death.

20 Sep 2019

Study opens a promising new front in the fight against pancreatic cancer

Pancreatic adenocarcinoma (PDAC) is a lethal malignancy that most often is resistant to chemotherapy. Researchers have been searching for ways to increase the sensitivity of the tumors to cancer-fighting drugs.

19 Sep 2019

New drug may enhance efficacy of chemotherapy in pancreatic cancer

One of the major obstacles in the treatment of pancreatic cancer is the 'defense wall' that is formed around the tumor.

5 Sep 2019

The gift of longevity for a pancreatic cancer patient

While weeding in her north Seattle garden, Miggie Olsson discusses how she, as a patient, became a unicorn.

30 Aug 2019

Study shows synergistic effects of drugs that inhibit cell division in pancreatic cancer

Pancreatic cancer is one of the deadliest cancers, with patients surviving on average less than a year once the disease has spread.

19 Aug 2019

Targeted pancreatic cancer drug shows promise in clinical trials

Researchers have conducted clinical trials with a new drug targeting pancreatic cancer and the initial results are promising.

16 Aug 2019

New drug to treat pancreatic cancer shows promising results in clinical trial

A clinical trial testing a new drug in pancreatic cancer had promising initial results, report researchers from the University of Michigan Rogel Cancer Center.

14 Aug 2019

Longer-lived, but less toxic drug may work better for pancreatic cancer

Unlike many other cancers, most pancreatic tumors are rock hard.

9 Aug 2019

Promising antibody therapy reduces tumor growth, increases survival in mice with pancreatic cancer

Scientists have found a way to target and knock out a single protein that they have discovered is widely involved in pancreatic cancer cell growth, survival and invasion.

31 Jul 2019

Scientists identify new way to target bottleneck for cancer cell growth

The enzyme ribonucleotide reductase is a bottleneck for cancer cell growth. Scientists at Winship Cancer Institute of Emory University have identified a way of targeting ribonucleotide reductase that may avoid the toxicity of previous approaches, informing focused drug discovery efforts.

23 Jul 2019

Prior radioprotection via EGLN inhibitor improves survival in mouse model of pancreatic cancer

Administration of the EGLN inhibitor FG-4592 prior to ablative radiotherapy provided protection against fatal gastrointestinal bleeding and improved survival in a mouse model of unresectable pancreatic cancer.

30 Apr 2019

Tumor-associated macrophages block activity of chemotherapy drug in pancreatic cancer

A frontline chemotherapy drug given to patients with pancreatic cancer is made less effective because similar compounds released by tumor-associated immune cells block the drug's action, research led by the University of Michigan Rogel Cancer Center found.

27 Mar 2019